Two independent studies found that a blood biomarker tied to Alzheimer’s disease also rises sharply in the brains of former football players with advanced chronic traumatic encephalopathy, a step toward diagnosing the condition in the living.
The research, published Thursday in JAMA, measured plasma levels of eMTBR-tau243 — a fragment of the tau protein that forms tangles inside neurons — in stored blood samples from men who later donated their brains. At Boston University and Banner Health, 18 of 21 former players had CTE at autopsy; 16 were classified as high-stage (III or IV). Their eMTBR-tau243 concentrations were significantly higher than in three donors without CTE and two with early-stage disease, the BU-led team reported. A separate Washington University group, using mass spectrometry on samples from 11 brain donors with CTE, reached the same conclusion: the biomarker tracked advanced CTE but not early stages.
“It’s very encouraging that two independent groups with two independent methods came to the same conclusion,” said Chihiro Sato, assistant professor of neurology at Washington University in St. Louis and co-corresponding author of the WashU study.
The BU study also found that five donors who had both CTE and Alzheimer’s disease showed the highest eMTBR-tau243 levels of all. A second Alzheimer’s biomarker, plasma p-tau217, was elevated in those five but not in donors with CTE alone, suggesting a two-marker panel could distinguish the diseases, Michael Alosco, co-director of clinical research at the BU CTE Center and co-senior author of the BU paper, told The Boston Globe.
“What was really quite striking was just the difference,” Alosco said. “The high-stage CTE concentrations were just so much higher than anyone else, and that really stood out.”
Richard McElroy, a former Mississippi State University lineman who died in January at 74, was among the BU participants. His wife, Janice Howard McElroy, said his personality changed in his early 50s — sudden rages, heavy drinking — and he was later diagnosed with stage 4 CTE.
“I still obviously wish it could have helped him, but it still makes us feel amazing that this can be his legacy,” their daughter Kristina McElroy told The Boston Globe.
Limitations are substantial. The BU cohort included only 21 donors, almost all with advanced disease, and few asymptomatic controls. “It’s really just a hint,” said Ramon Diaz-Arrastia, a neurology professor at the University of Pennsylvania Perelman School of Medicine who was not involved in either study. “The sample size was way too small for us to make any guesses and any estimates as to what the diagnostic thresholds and things like that are.”
Derek Monroe, an assistant professor of exercise and sport science at UNC Chapel Hill, added that the participants are not representative of all football players or the broader population.
“Before we know how this test performs, it must be studied in a broader group of people: those with and without a history of head impacts, with and without symptoms, followed over time,” he told The Boston Globe.
An accompanying editorial by Günter Höglinger and Carla Palleis of Ludwig Maximilian University of Munich noted that tau pathology in CTE differs structurally from Alzheimer’s, and abnormal tau appears in several other neurodegenerative diseases, complicating specificity.
Both studies’ authors acknowledged the work remains in the “discovery phase.”
Alosco said larger validation studies are feasible because brain-donation rates are rising. “In a not so distant future, we’ll be able to do a larger one of these studies to validate it in a bigger sample,” he told The Boston Globe. “If the findings hold up with future studies, this is really going to change the landscape.”
What the biomarker measures
eMTBR-tau243 is an endogenously cleaved fragment of the microtubule-binding region of tau. In Alzheimer’s, tau tangles spread through the cortex in a stereotyped pattern. In CTE, tau accumulates around blood vessels at the depths of cortical sulci, a distinct “pathognomonic” lesion. The fact that the same plasma fragment rises in advanced CTE suggests that late-stage neurodegeneration releases similar tau fragments regardless of the initial trigger, researchers said.
How the two studies differed
| Feature | Boston University / Banner Health | Washington University in St. Louis |
|---|---|---|
| Cohort | 21 former football players (pro, college, high school) | 11 brain donors with CTE (sport exposures not uniformly detailed) |
| CTE cases | 18 (16 high-stage, 2 low-stage) | 11 (staging distribution not specified in abstract) |
| Assay | Immunoassay for eMTBR-tau243 | Mass spectrometry for eMTBR-tau243 |
| Key finding | High-stage CTE > low-stage > controls; highest in CTE+AD | Elevated in advanced CTE vs. controls; not reliable for early CTE |
Why a blood test matters
CTE can today be confirmed only by post-mortem brain examination. That barrier has obscured prevalence, blocked clinical trials, and left symptomatic former athletes without a definitive diagnosis. A validated blood test would allow researchers to enroll living participants in therapeutic trials, track disease progression, and eventually give clinicians a tool to differentiate CTE from Alzheimer’s, frontotemporal dementia, and other mimics.
An October study from the BU CTE Center estimated that nearly three-quarters of NFL players who died between 2008 and 2023 had CTE, the highest prevalence estimate to date. The disease has also been documented in former hockey, rugby, and soccer players and in military veterans exposed to blast waves.

Open questions
- Diagnostic thresholds that balance sensitivity and specificity in a diverse, symptomatic population.
“Ultimately, I do not think any single marker will solve this,” Monroe said. “The more realistic path is a combination of tools.”
FDA has not approved blood test for CTE
Can I get this blood test today?
The FDA has not approved any blood test for CTE, and the authors emphasize the findings are preliminary.
Does the test detect early CTE?
Not reliably. Both studies found the biomarker distinguished advanced (stage III/IV) CTE from controls but lacked sensitivity for early-stage (I/II) disease.
How is CTE different from Alzheimer’s?
Both involve tau tangles, but the distribution and conformation differ. CTE tau clusters around small vessels at the bottom of cortical sulci; Alzheimer’s tau spreads through the medial temporal lobe and neocortex in a hierarchical pattern. Clinically, CTE often presents earlier with behavioral and mood changes, while Alzheimer’s typically begins with memory impairment.
Boston University, where the CTE Center is based, traces its origins to a Methodist theological school founded in Newbury, Vermont, in 1839 and chartered in Boston in 1869. It is a private research university with nearly 38,000 students and more than 4,000 faculty members, classified among institutions with very high research activity.
Who funded the research?
The BU study was supported by the National Institutes of Health, the Department of Veterans Affairs, and the Concussion Legacy Foundation, among others. The WashU study received NIH funding and support from the Alzheimer’s Association.